WOBURN, Mass., Feb. 12 /PRNewswire/ -- AdvanDx announced it has named Else Beth Trautner, a former Executive Vice President of Dako A/S, as Vice President of Sales and Marketing. Ms. Trautner will aggressively drive the global adoption of AdvanDx's fast, accurate and easy-to-use in vitro molecular diagnostic products that advance the prevention, diagnosis and treatment of infectious pathogens. Ms. Trautner previously managed an organization of more than 575 employees with annual revenues in excess of $300 million at Dako, a global cancer diagnostics company, while successfully restructuring business operations in the Asia-Pacific region that led to record sales. Ms. Trautner also orchestrated the reorganization of 22 sales subsidiaries into 5 geographic regions resulting in 15% sales growth and a 9% increase in profitability during her tenure as Executive Vice President of Global Sales at Dako.
"Ms. Trautner is a seasoned executive with proven industry experience who will drive aggressive growth, market expansion, revenue production and ultimately profitability," said Thais T. Johansen, President and CEO of AdvanDx. "The addition of Ms. Trautner clearly positions AdvanDx to deliver our easy-to-use, life saving molecular diagnostic products worldwide to help treat patients afflicted with serious infections," Mr. Johansen added.
"I am pleased to join AdvanDx's strong business and scientific management team as we make significant inroads into multi-billion dollar markets," said Else Beth Trautner, Vice President of Sales and Marketing at AdvanDx. "I look forward to ramping our success in North America while opening up new markets, seizing revenue-generating sales opportunities and further accelerating the adoption of our products in the global marketplace," said Ms. Trautner.
AdvanDx is the world's leading provider of fast, accurate and easy-to-use in vitro molecular diagnostic products that advance the prevention, diagnosis and treatment of infectious pathogens. AdvanDx's products and services enable dramatic improvements in patient care and outcomes while reducing hospital costs.
Every year, 350,000 patients contract bloodstream infections, causing over 90,000 unnecessary deaths and significant costs to the healthcare system. The rapid identification of infecting pathogens is crucial to ensure early and appropriate therapy to save lives and reduce patient length-of-stay. In response, AdvanDx leverages its molecular diagnostic products to detect and identify infectious pathogens and provide therapy-directing results in hours versus days.
AdvanDx's easy-to-use products employ standard lab techniques and equipment to reduce startup, implementation, technician and maintenance time, while providing fast results without sacrificing accuracy. Major medical centers, reference labs, government institutions and community hospitals throughout the United States, Europe and Asia rely on AdvanDx products, supported by a global network of service partners.
For more information visit http://www.AdvanDx.com
Copyright©2008 PR Newswire.
All rights reserved